Valion Bio, Inc.
VBIO
$0.56
-$0.02-3.88%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
6/25/2026
-
GuruFocus
6/25/2026
-
PR Newswire
6/24/2026
-
The Cerbat Gem
6/18/2026
-
TipRanks
6/11/2026
-
GuruFocus
6/11/2026
-
PR Newswire
6/4/2026
-
The Cerbat Gem
5/19/2026
-
PR Newswire
5/14/2026
-
The Cerbat Gem
5/14/2026
-
TipRanks Financial Blog
Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work
5/14/2026
-
Seeking Alpha - Healthcare
Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work
5/14/2026
-
SeekingAlpha.com: All News
5/14/2026
-
SeekingAlpha
5/14/2026
-
Seeking Alpha: Transcripts
5/14/2026
-
PR Newswire
5/14/2026
-
PR Newswire
5/11/2026
-
PR Newswire
5/6/2026
-
PR Newswire
5/5/2026
-
PR Newswire
5/4/2026
-
TipRanks Financial Blog
5/4/2026
-
TipRanks Financial Blog
5/4/2026
-
The Fly
5/4/2026
-
PR Newswire
4/28/2026
-
PR Newswire
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, March 30, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
(est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
888 276 6888
Address
1305 E. Houston Street
San Antonio, TX 78205
San Antonio, TX 78205
Country
Year Founded
Business Description
Sector
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The...
more